IBRX
ImmunityBio·NASDAQ
--
--(--)
--
--(--)
6.35 / 10
Outperform
Fund flow evaluation: 7.86/10 reflecting robust fund flow characteristics. Constructive overall, block, Small, Medium, and Extra-large trends face headwinds from adverse Large developments, indicating positive money flow direction. Analyst coverage indicates overwhelmingly bullish analyst consensus with strong conviction. Rating distribution: Strong Buy(85.7%), Buy(14.3%) among 7 analysts, supported by 4.83 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
86%
Buy
14%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-26
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for IBRX?
- IBRX holds a Bearish analyst rating, with 86% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.35/10 (Outperform).
